Age-Related Macular Degeneration, Third Edition

The value of Age-Related Macular Degeneration has stood the test of time, but progress in both basic and clinical ophthalmology has been relentless, mandating the need for an updated book. This second edition focuses on the pathophysiology and the epidemiology of age-related macular degeneration (AMD), the clinical features and management of dry and wet AMD, imaging techniques, and medical therapy for both non-neovascular AMD and neovascular AMD. It describes both clinically validated and experimental therapies as well as rehabilitation technology, and presents strategies to prevent the progression of non-exudative AMD. Results from current clinical trials are also included. New chapters in this edition cover: Genetics and treatment Oxidative stress and its relation to the pathophysiology of AMD and CNV (choroidal neovascularization—a common symptom of wet AMD) Polypoidal choroidal vasculopathy Microperimetry and psychophysical testing and ways to track geographic atrophy progression Non-VEGF pathways Retinal stem cells

Pathophysiology and Epidemiology of AMD Histopathology of Age-Related Macular Degeneration Immunology of Age-Related Macular Degeneration Genetics of Age-Related Macular Degeneration Choroidal Neovascularization: VEGF Pathways Risk factors for Age-Related Macular Degeneration and Choroidal Neovascularization Oxidative Stress Clinical Features of AMDGeographic Atrophy Non-Neovascular Age-Related Macular Degeneration Neovascular Age-Related Macular Degeneration Polypoidal Choroidal Vasculopathy Variants of Neovascular Age-related Macular Degeneration: Type 3 Neovascularization (Intra-retinal Neovascularization or Retinal Angiomatous Proliferation) Imaging Techniques for the Clinical Evaluation of AMDFluorescein Angiography in Age-related Macular Degeneration Indocyanine Green Angiography in Age-Related Macular Degeneration Optical Coherence Tomography in the Evaluation of Age-Related Macular Degeneration How to Analyze OCT images for Management of Neovascular AMD Fundus Autofluorescence Imaging in Age-Related Macular Degeneration Microperimetry and Psychophysical Testing to Aid in Determination of Progression of AMD Current and Experimental Medical Treatment for Neovascular AMDLaser Photocoagulation for Choroidal Neovascularization Anti-VEGF drugs and Clinical trials Non-VEGF Related Anti-Angiogenesis Pathways for Treatment of AMD Radiation Therapy Treatment in Age-Related Macular Degeneration Combination Therapy for AMD Photodynamic Therapy for Neovascular AMD Photocoagulation of AMD-Associated CNV Feeder VesselsMacular Translocation and Other Surgical Treatments Current and Experimental Medical Treatment for Non-Neovascular AMD and Geographic Atrophy Prophylactic Treatment: The AREDS Study Results Visual Cycle Modulation Cellular Transplantation for Advanced Age-Related Macular Degeneration Novel Therapeutic Interventions: Stem Cell Rehabilitation of the EyeClinical Considerations for Visual RehabilitationVisual Prostheses for Age-Related Macular DegenerationDevelopment of Research Protocols in AMDClinical Research Trials

Jennifer I. Lim, M.D. is a professor of ophthalmology, Department of Ophthalmology; Director of the Retina Service; Marion H. Schenk, Esq. Chair in Ophthalmology for Research of the Aging Eye, at the University of Illinois at Chicago. Dr Lim has contributed to over 90 courses, and has published over 200 academic papers, contributed to over 20 book chapters and published 4 books in total. She has given over 150 presentations at scientific meetings and has been invited to over 130 lectures/visiting professorships. Dr Lim is a reviewer for a number of academic journals including the American Journal of Ophthalmology, Retina, and the British Journal of Ophthalmology. She is currently a committee member for the Macula Society, American Society of Retinal Specialists, and American Academy of Ophthalmology. Recent Awards: •Marion H. Schenk, Esq., Chair in Ophthalmology for Research of the Aging Eye, 2010•Best Doctors in America 2010-2011 (initially and continuously selected since 1994)